Chengdu MedGenCell

Company type: Therapeutics

Main focus: Gene editing for the development of cellular therapies

Company stage: Clinical

Diseases: Haematological and solid tumours

Genome-editing tool: CRISPR

Funding stage: Private

Location: Chengdu, China

Shanghai IASO Biotechnology develops next-generation CAR-T cell therapies, and uses CRISPR to knock out certain genomic targets to improve the efficacy and safety of its cellular products.

See the full view ...